Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?

Katherine Esposito, Antonio Ceriello, Dario Giugliano

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Uncertainties abound in clinical management of type 2 diabetes. Sources of uncertainty specific to type 2 diabetes originate from the panoply of glycemic (HbA1c) targets, the complexity of drug therapy, the ideal sequence of drugs after metformin failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat in order to prevent the vascular complications. Ironically, multiple treatment guidelines and algorithms periodically released to improve guidance may generate confusion into clinicians. Moreover, treatment algorithms cannot be truly evidence-based because of a lack of studies comparing all available treatment combination options. Personalized therapy essentially identifies patients who could have major benefits from the therapy as compared with other patients. Personalized medicine for type 2 diabetic has the potential to improve the quality health-care practice of diabetes management, but specific research is needed.

Original languageEnglish
Pages (from-to)343-345
Number of pages3
JournalEndocrine
Volume44
Issue number2
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Type 2 Diabetes Mellitus
Uncertainty
Therapeutics
Precision Medicine
Quality of Health Care
Metformin
Practice Management
Pharmaceutical Preparations
Blood Vessels
Guidelines
Drug Therapy
Research

Keywords

  • Clinical management
  • Personalized medicine
  • Type 2 diabetes
  • Uncertainty

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? / Esposito, Katherine; Ceriello, Antonio; Giugliano, Dario.

In: Endocrine, Vol. 44, No. 2, 10.2013, p. 343-345.

Research output: Contribution to journalArticle

@article{57aed7c964aa4ba29ffefcfb150ebbfe,
title = "Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?",
abstract = "Uncertainties abound in clinical management of type 2 diabetes. Sources of uncertainty specific to type 2 diabetes originate from the panoply of glycemic (HbA1c) targets, the complexity of drug therapy, the ideal sequence of drugs after metformin failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat in order to prevent the vascular complications. Ironically, multiple treatment guidelines and algorithms periodically released to improve guidance may generate confusion into clinicians. Moreover, treatment algorithms cannot be truly evidence-based because of a lack of studies comparing all available treatment combination options. Personalized therapy essentially identifies patients who could have major benefits from the therapy as compared with other patients. Personalized medicine for type 2 diabetic has the potential to improve the quality health-care practice of diabetes management, but specific research is needed.",
keywords = "Clinical management, Personalized medicine, Type 2 diabetes, Uncertainty",
author = "Katherine Esposito and Antonio Ceriello and Dario Giugliano",
year = "2013",
month = "10",
doi = "10.1007/s12020-013-9918-x",
language = "English",
volume = "44",
pages = "343--345",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press Inc.",
number = "2",

}

TY - JOUR

T1 - Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?

AU - Esposito, Katherine

AU - Ceriello, Antonio

AU - Giugliano, Dario

PY - 2013/10

Y1 - 2013/10

N2 - Uncertainties abound in clinical management of type 2 diabetes. Sources of uncertainty specific to type 2 diabetes originate from the panoply of glycemic (HbA1c) targets, the complexity of drug therapy, the ideal sequence of drugs after metformin failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat in order to prevent the vascular complications. Ironically, multiple treatment guidelines and algorithms periodically released to improve guidance may generate confusion into clinicians. Moreover, treatment algorithms cannot be truly evidence-based because of a lack of studies comparing all available treatment combination options. Personalized therapy essentially identifies patients who could have major benefits from the therapy as compared with other patients. Personalized medicine for type 2 diabetic has the potential to improve the quality health-care practice of diabetes management, but specific research is needed.

AB - Uncertainties abound in clinical management of type 2 diabetes. Sources of uncertainty specific to type 2 diabetes originate from the panoply of glycemic (HbA1c) targets, the complexity of drug therapy, the ideal sequence of drugs after metformin failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat in order to prevent the vascular complications. Ironically, multiple treatment guidelines and algorithms periodically released to improve guidance may generate confusion into clinicians. Moreover, treatment algorithms cannot be truly evidence-based because of a lack of studies comparing all available treatment combination options. Personalized therapy essentially identifies patients who could have major benefits from the therapy as compared with other patients. Personalized medicine for type 2 diabetic has the potential to improve the quality health-care practice of diabetes management, but specific research is needed.

KW - Clinical management

KW - Personalized medicine

KW - Type 2 diabetes

KW - Uncertainty

UR - http://www.scopus.com/inward/record.url?scp=84885583673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885583673&partnerID=8YFLogxK

U2 - 10.1007/s12020-013-9918-x

DO - 10.1007/s12020-013-9918-x

M3 - Article

VL - 44

SP - 343

EP - 345

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 2

ER -